This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis Announces Positive Long-Term Data on Migraine Drug
by Zacks Equity Research
Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?
by Zacks Equity Research
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Why Novartis (NVS) Stock Might be a Great Pick
by Zacks Equity Research
Novartis (NVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Global Blood Focuses on Lead Candidate Amid Competition
by Zacks Equity Research
Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry
by Zacks Equity Research
Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.
AstraZeneca's Lupus Drug Meets Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer
by Zacks Equity Research
Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
by Christopher Vargas
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
by Zacks Equity Research
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease
by Zacks Equity Research
AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.
Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
by Sweta Killa
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?
Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
by Zacks Equity Research
Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
by Zacks Equity Research
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
Teva Launches Generic Version of Mylan's EpiPen for KIds
by Zacks Equity Research
Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.